Transaction DateRecipientSharesTypePriceValue
26th October 2020Mark T Iwicki178,300Grant/award etc.$0.00
13th October 2020Douglas T. Sheehy36,875Sale back to the issuer$34.50$1,272,187.50
13th October 2020Mark T Iwicki7,840Sale back to the issuer$34.50$270,480.00
13th October 2020Patrick G Enright7,840Sale back to the issuer$34.50$270,480.00
13th October 2020Des Produits Nestle S.A. Societe43,435,583Open or private purchase$34.50$1,498,527,613.50
13th October 2020Kathryn E Falberg7,840Sale back to the issuer$34.50$270,480.00
13th October 2020Gregory Behar7,840Sale back to the issuer$34.50$270,480.00
13th October 2020Gregory Behar10,192Other acquisition or disposition$0.00
13th October 2020Brett K Haumann13,313Sale back to the issuer$34.50$459,298.50
13th October 2020Des Produits Nestle S.A. Societe10,681,704Open or private purchase$34.50$368,518,788.00
Aimmune Therapeutics
Aimmune Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.


Ticker: AIMT
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1631650
Employees: 275
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $267 M (233%)
Inventory, Net: $6 M (0%)
Assets, Current: $324 M (117%)
Property, Plant and Equipment, Net: $27 M (0%)
Assets: $365 M (78%)
Accounts Payable, Current: $15 M (8%)
Accrued Liabilities, Current: $25 M (0%)
Liabilities, Current: $43 M (-9%)
Long-term Debt, Excluding Current Maturities: $131 M (0%)
Other Liabilities, Noncurrent: $2 M (22%)
Liabilities: $185 M (84%)
Common Stock, Value, Issued: $7 Th (16%)
Common Stock, Shares, Issued: $65 Th (2%)
Additional Paid in Capital, Common Stock: $1 B (27%)
Retained Earnings (Accumulated Deficit): $880 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $239 Th (198%)
Stockholders' Equity (Parent): $180 M (0%)
Liabilities and Equity: $365 M (78%)
Research and Development: $23 M (-61%)
Operating Income/Loss: $66 M (-56%)
Provision for income taxes: $321 Th (-27%)